Home
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
Company Overview
Corporate Strategy
Management Team
Venture Partners
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
中国 — 简体中文
Global — English
Home
Technology Platforms
BACK
Technology Platforms
Harbour Mice
®
Single Cell Technology Platform
HBICE
®
Fully Human Generative AI HCAb Model
Therapeutics
BACK
Therapeutics
Inflammatory & Immunology Diseases
Oncology/Immuno-Oncology
Weight Management
Publications
Harbour Medical
BACK
Harbour Medical
Overview
Clinical Development & Medical Services
Scientific Committee
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Partnership
BACK
Partnership
Technology Service
Technology License
Asset License
Co-development
Strategic Collaboration
Cooperation Contact
About Us
BACK
About Us
Company Overview
Corporate Strategy
Management Team
Venture Partners
Scientific Advisory Board
Our History
Our Locations
Newsroom
Investor Relations
BACK
Investor Relations
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Careers
Investor Relations
Effective Communication Drives Development
Corporate Governance
Stock Information
Disclosure
Financials
Presentations and Events
Analyst Coverage
Notices-Replacement of Lost Share Certificates
Subscribe to Updates
Home
>
Investor Relations
>
Disclosure
Disclosure
Listing Documents
Financial Report/ESG information
Announcement & Notice
IR Journal
2023-05-09
CLARIFICATION ANNOUNCEMENT IN RELATION TO CIRCULAR, NOTICE OF ANNUAL GENERAL MEETING AND FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 8 JUNE 2023
2023-05-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
2023-04-28
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
2023-04-28
NOTICE OF ANNUAL GENERAL MEETING
2023-04-28
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING
2023-04-19
GRANT OF SHARE OPTIONS AND GRANT OF SHARE AWARDS
2023-04-14
VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE IB CLINICAL TRIAL OF PORUSTOBART (HBM4003) IN COMBINATION WITH TORIPALIMAB IN ADVANCED HIGH-GRADE NEUROENDOCRINE NEOPLASMS
2023-04-12
Next Day Disclosure Return
2023-04-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
2023-03-31
Next Day Disclosure Returns
2023-03-30
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2022
2023-03-17
DATE OF BOARD MEETING
2023-03-06
VOLUNTARY ANNOUNCEMENT - POSITIVE TOPLINE RESULTS FROM PHASE III TRIAL OF BATOCLIMAB (HBM9161) FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
2023-02-14
INSIDE INFORMATION ENTERING INTO LICENSE AND COLLABORATION AGREEMENT WITH CULLINAN ONCOLOGY, INC. FOR HBM7008
2023-02-07
VOLUNTARY ANNOUNCEMENT - FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES INDCLEARANCE FOR HBM1022 CLINICAL TRIAL INITIATION
2023-01-13
VOLUNTARY ANNOUNCEMENT - FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES IND CLEARANCE FOR HBM1020 CLINICAL TRIAL INITIATION
2023-01-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
2022-12-23
INSIDE INFORMATION - FURTHER BUSINESS UPDATE ON COLLABORATION WITH KELUN-BIOTECH IN CONNECTION WITH ANTIBODY-DRUG CONJUGATE
2022-12-23
SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION DISPOSAL OF ASSETS
2022-12-09
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE OF COLLABORATION WITH KELUN-BIOTECH
1
···
15
16
17
···
22
Jump